CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study. [J]. Annals of Hematology. Accepted, 2018

Delayed terminal lleal perforation in a relapsed/refractory B-Cell lymphoma patient with remission following chimeric antigen receptor T cell therapy[J]. Cancer Research and treatment. Accepted, 2018

Hu Y, Wu Z, Luo Y, Shi J, Yu J, Pu C, Liang Z, Wei G, Cui Q, Sun J, Jiang J, Xie J, Tan Y, Ni W, Tu J, Wang J, Jin A, Zhang H, Cai Z, Xiao L, Huang H. Potent anti-leukemia activities of chimeric antigen receptor modified T cells against CD19 in Chinese patients with relapsed/refractory acute lymphocytic [J]. Clin Cancer Res. 2016 Dec 30.

Hu Y, Sun J, Wu Z, Yu J, Cui Q, Pu C, Liang B, Luo Y, Shi J, Jin A, Xiao L, Huang H. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy[J]. Journal of Hematology & Oncology, 2016, 9(1):70.

Yu J, Hu Y, Pu C, et al. Successful chimeric Ag receptor modified T cell therapy for isolated testicular relapse after hematopoietic cell transplantation in an acute lymphoblastic leukemia patient[J]. Bone Marrow Transplantation, 2017, 52(7).

Pleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified Tcell therapy: A case report. 2018.Accepted.

Chen Y, Cheng Y, Suo P, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.[J]. British Journal of Haematology, 2017.

Zhu YM, Wu Z, Tan YP, Du YY, Liu Z, Ou RM, Liu S, Pu CF, Jiang J, Wang JP, Xiao L, Zhang Q. Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia: Two case reports.[J]. Medicine, 2016, 95(51).